Phase I/II study of TLC D-99 [doxorubicin HCl liposome] plus Herceptin [trastuzumab] as first or second line therapy for patients with locally advanced inflammatory or metastatic breast cancer.
Phase of Trial: Phase I/II
Latest Information Update: 02 Jun 2015
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Sep 2005 New trial record.